Remsima®SC is the world's first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency(EMA), Korean Ministry of Food and Drug Safety(MFDS) and Health Canada.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.